In 2019, the US FDA approved a new treatment for women suffering from low sexual desire with distress. Known as bremelanotide, it mimics a substance naturally found in the brain, known as a melanocortin. This study investigated how well this new drug worked to improve low desire and its related distress in women, next to several other sexual health indicators.
